为什么拜瑞妥在中国卖这么贵?拜瑞妥多少钱？

Xarelto is an oral, bioavailable Factor Xa inhibitor that selectively blocks the active site of Factor Xa and does not require cofactors (such as antithrombin III) for activity. It is the world's first oral direct factor Xa inhibitor developed by Bayer. Today let’s find out why Xarelto is so expensive in China? How much does Xarelto cost?

Xarelto is already on the market in China and has been included in the national medical insurance, but the financial burden is still heavy. Patients in need can obtain the drug through domestic professional overseas medical service organizations (such as Medical Companion Travel). The price is not fixed due to exchange rate fluctuations. For specific prices, please consult Medical Companion Travel Service. By inhibiting factor xa, Xarelto can interrupt the endogenous and exogenous pathways of the coagulation waterfall, inhibit the generation of thrombin and thrombosis, and has a safe, effective, simple and intuitive anticoagulant effect. This is also the reason why the price is more expensive.

As a new oral anticoagulant drug, Xarelto's efficacy in preventing deep vein thrombosis in the lower limbs after hip replacement has been confirmed by numerous studies by scholars. Foreign literature points out that extending the treatment course to 35 days can more significantly reduce the incidence of deep vein thrombosis.

A total of 106 patients who underwent primary unilateral hip replacement were selected and randomly divided into the rivaroxaban group and the low molecular weight heparin group. Both groups were administered rivaroxaban 6 hours after replacement. The Xarelto rivaroxaban group was given 10 mg/d for a 5-week course of treatment; the low-molecular-weight heparin group was 4100 U/d for a 2-week course of treatment.

Results and conclusion: No deep vein thrombosis and no deep vein thrombosis symptoms were found in patients with unilateral hip replacement in the Xarelto rivaroxaban group during post-replacement review and follow-up. In the low molecular weight heparin group, 7 cases (13%) of patients with unilateral hip replacement were found to have deep vein thrombosis. The difference in the incidence of deep vein thrombosis between the two groups was significant (P<0.05).

There was no significant difference in venous blood hemoglobin levels, platelet levels, coagulation function, post-replacement drainage volume and subcutaneous ecchymosis area between the two groups of unilateral hip replacement patients before and after replacement (P0.05). It is suggested that the application of rivaroxaban in the foot treatment after hip replacement has clear efficacy in preventing deep vein thrombosis, and the application of rivaroxaban in the foot treatment has reliable safety.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.